hydroxyindoleacetic acid and lutetium lu 177 dotatate

hydroxyindoleacetic acid has been researched along with lutetium lu 177 dotatate in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Blažević, A; Brabander, T; de Herder, WW; Feelders, RA; Hofland, J; Minczeles, NS; Zandee, WT	1

Other Studies

1 other study(ies) available for hydroxyindoleacetic acid and lutetium lu 177 dotatate

Article	Year
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. The Journal of clinical endocrinology and metabolism, 2021, 08-18, Volume: 106, Issue:9 Topics: Aged; Aged, 80 and over; Cohort Studies; Diarrhea; Drug Resistance, Neoplasm; Female; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Quality of Life; Radioisotopes; Receptors, Peptide; Retrospective Studies; Somatostatin; Treatment Outcome	2021

Article

Year

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.

The Journal of clinical endocrinology and metabolism, 2021, 08-18, Volume: 106, Issue:9

Topics: Aged; Aged, 80 and over; Cohort Studies; Diarrhea; Drug Resistance, Neoplasm; Female; Humans; Hydroxyindoleacetic Acid; Male; Malignant Carcinoid Syndrome; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Quality of Life; Radioisotopes; Receptors, Peptide; Retrospective Studies; Somatostatin; Treatment Outcome

2021